Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials

References

• Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Published 2020 Dec 2;21(1):137. DOI:10.1186/s10194-020-01208-0
   PubMed Web of Science ®Google Scholar
• Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders. 3rd. Cephalalgia. 2018;38(1):1–211. DOI:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Baca SM, Akerman S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab. 2019;39(4):573–594.
   PubMed Web of Science ®Google Scholar
• Recober A. Pathophysiology of Migraine. Continuum (Minneap Minn). 2021;27(3):586–596.
   PubMedGoogle Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61. DOI:10.1046/j.1468-2982.2002.00310.x
   PubMed Web of Science ®Google Scholar
• Mavridis T, Deligianni CI, Karagiorgis G, et al. Monoclonal antibodies targeting CGRP: from clinical studies to real-world evidence-what do we know so far?Pharmaceuticals (Basel). [Published 2021 Jul 20] 2021;14(7):700. DOI:10.3390/ph14070700
   PubMedGoogle Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567.
   PubMed Web of Science ®Google Scholar
• Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. New generation gepants: migraine acute and preventive medications.J Clin Med. [Published 2022 Mar 16] 2022;11(6):1656. DOI:10.3390/jcm11061656
   PubMed Web of Science ®Google Scholar
• Lanteri-Minet M. Economic burden and costs of chronic migraine. Curr Pain Headache Rep. 2014;18(1):385.
   PubMed Web of Science ®Google Scholar
• Khanal S, Underwood M, Naghdi S, et al. A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine. J Headache Pain. 2022 Published 2022 Sep 16;23(1):122. DOI:10.1186/s10194-022-01492-y
   PubMed Web of Science ®Google Scholar
• Burch R. Preventive migraine treatment [published correction appears in Continuum (Minneap Minn). 2021 Oct 1;27(5): 1494-1495]. Continuum (Minneap Minn). 2021;27(3):613–632.
   PubMedGoogle Scholar
• Buse DC, Rupnow MF, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422–435.
   PubMed Web of Science ®Google Scholar
• Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27(3):220–229. DOI:10.1111/j.1468-2982.2006.01275.x
   PubMed Web of Science ®Google Scholar
• Yuan D, Zhang Y, Li Q, et al. Factors affecting preventive treatment outcomes for patients with newly diagnosed chronic migraine and their compliance with treatment recommendations in Chongqing Province, China: an Open-Label Prospective Study with Retrospective Baseline. Front Neurol. [Published 2020 Apr 9] 2020;11:227.
   PubMed Web of Science ®Google Scholar
• Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol. 2008;10(1):20–29.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349. DOI:10.1212/01.wnl.0000252808.97649.21
   PubMed Web of Science ®Google Scholar
• D’Amico D, Tepper SJ, D’Amico D. Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat. 2008;4(6):1155–1167.
   PubMedGoogle Scholar
• Sprenger T, Viana M, Tassorelli C. Current prophylactic medications for migraine and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):313–323.
   PubMed Web of Science ®Google Scholar
• Galletti F, Cupini LM, Corbelli I, et al. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol. 2009;89(2):176–192.
   PubMed Web of Science ®Google Scholar
• Scuteri D, Adornetto A, Rombolà L, et al. New trends in migraine pharmacology: targeting calcitonin Gene-Related Peptide (CGRP) with monoclonal antibodies. Front Pharmacol. [Published 2019 Apr 9] 2019;10:363.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis. PLoS ONE. 2019 Published 2019 Mar 20;14(3):e0212785. DOI:10.1371/journal.pone.0212785.
   PubMed Web of Science ®Google Scholar
• Goldberg MR, Sciberras D, De Smet M, et al. Influence of β-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT 1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol. 2001;52(1):69–76. DOI:10.1046/j.0306-5251.2001.01417.x
   PubMed Web of Science ®Google Scholar
• Bergman JEH, Lutke LR, Gans ROB, et al. Beta-blocker use in pregnancy and risk of specific congenital anomalies: a european case-malformed control study. Drug Saf. 2018;41(4):415–427. DOI:10.1007/s40264-017-0627-x
   PubMed Web of Science ®Google Scholar
• Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006.
   Google Scholar
• Farzam K, Jan A. Beta Blockers. In: StatPearls. Treasure Island (FL):StatPearls Publishing; 2023 Jan.
   Google Scholar
• Xu XM, Liu Y, Dong MX, et al. Tricyclic antidepressants for preventing migraine in adults. Medicine (Baltimore). 2017;96(22):e6989.
   PubMed Web of Science ®Google Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–748.
   PubMed Web of Science ®Google Scholar
• Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005;45(2):144–152.
   PubMed Web of Science ®Google Scholar
• Hedayat M, Nazarbaghi S, Heidari M, et al. Venlafaxine can reduce the migraine attacks as well as amitriptyline: a noninferiority randomized trial. Clin Neurol Neurosur. 2022;214:107151.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the american academy of neurology and the American Headache Society [published correction appears in Neurology. Neurology. [2013 Feb 26] 2012;8078(917):1337–1345.
   Web of Science ®Google Scholar
• Line M, Mulleners WM, Chronicle EP, et al. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(Issue 6). Art. No.:CD010611.
   Web of Science ®Google Scholar
• Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. long-term safety of depakote in headache prophylaxis study group. Headache. 1999;39(9):633–643.
   PubMedGoogle Scholar
• White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache. 2005;45(Suppl 1):S48–56.
   PubMed Web of Science ®Google Scholar
• Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;2013(6): CD010610. Published 2013 Jun 24.
   Google Scholar
• Luykx J, Mason M, Ferrari MD, et al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther. 2009;85:283–288. 92.
   PubMed Web of Science ®Google Scholar
• Adelman J, Freitag FG, Lainez M, et al. Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials. Pain Med. 2008;9(2):175–185.
   PubMed Web of Science ®Google Scholar
• Tsai MJ, Chen YT, Ou SM, et al. Increased risk of urinary calculi in patients with migraine: a nationwide cohort study. Cephalalgia. 2015;35(8):652–661.
   PubMed Web of Science ®Google Scholar
• Abtahi MA, Abtahi SH, Fazel F, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol. 2012;6:117–131.
   PubMedGoogle Scholar
• Alsaad AM, Chaudhry SA, Koren G. First trimester exposure to topiramate and the risk of oral clefts in the offspring: a systematic review and meta-analysis. Reprod Toxicol. 2015;53:45–50.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–936.
   PubMed Web of Science ®Google Scholar
• Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358–1373.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Tedeschi G, Sarchielli P, et al. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Rev Neurother. 2018;18(2):167–176.
   PubMed Web of Science ®Google Scholar
• Szok D, Csati A, Vecsei L, et al. Treatment of chronic migraine with onabotulinumtoxinA: mode of action, efficacy and safety. Toxins (Basel). 2015;7(7):2659–2673. DOI:10.3390/toxins7072659
   PubMed Web of Science ®Google Scholar
• Masters-Israilov A, Robbins MS. OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine. Headache. 2019;59(10):1753–1761.
   PubMed Web of Science ®Google Scholar
• Ornello R, Baraldi C, Ahmed F, et al. Excellent Response to OnabotulinumtoxinA: different Definitions, different predictors. Int J Environ Res Public Health. [Published 2022 Sep 2] 2022;19(17):10975.
   PubMed Web of Science ®Google Scholar
• Ahmed F, Gaul C, García-Moncó JC, et al. REPOSE Principal Investigators. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. [Published 2019 Mar 7] 2019;20(1):26.
   PubMedGoogle Scholar
• Karsan N, Palethorpe D, Rattanawong W, et al. Flunarizine in migraine-related headache prevention: results from 200 patients treated in the UK. Eur J Neurol. 2018;25(6):811–817.
   PubMed Web of Science ®Google Scholar
• Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289(1):65–69.
   PubMed Web of Science ®Google Scholar
• Dorosch T, Ganzer CA, Lin M, et al. Efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the preventative treatment of episodic migraine in adults. Curr Pain Headache Rep. [Published 2019 Sep 12] 2019;23(11):85.
   PubMed Web of Science ®Google Scholar
• Wöber C, Brücke T, Wöber-Bingöl C, et al. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia. 1994;14(3):235–240. DOI:10.1046/j.1468-2982.1994.014003235.x
   PubMed Web of Science ®Google Scholar
• Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily [published correction appears in Cephalalgia. 2002 Jul;22(6): 488]. Cephalalgia. 2002;22(3):209–221. DOI:10.1046/j.1468-2982.2002.t01-1-00309.x
   PubMed Web of Science ®Google Scholar
• Nisar A, Ahmed Z, Yuan H. Novel therapeutic targets for migraine. Biomedicines. 2023;11(2):569.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Borsook D, Maleki N, Becerra L, et al. Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron. 2012;73(2):219–234.
   PubMed Web of Science ®Google Scholar
• Silvestro M, Tessitore A, Caiazzo G, et al. Disconnectome of the migraine brain: a “connectopathy” model. J Headache Pain. [Published 2021 Aug 28] 2021;22(1):102.
   PubMed Web of Science ®Google Scholar
• Russo A, Silvestro M, Trojsi F, et al. Cognitive networks disarrangement in patients with migraine predicts cutaneous allodynia. Headache. 2020;60(7):1228–1243.
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, Do TP, et al. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol. 2019;18(8):795–804.
   PubMed Web of Science ®Google Scholar
• Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013;154 Suppl 1.
   Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019;39(9):1075–1085. DOI:10.1177/0333102419858355
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254. DOI:10.1177/0333102420905132
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: pROMISE-2. Neurology. 2020;94(13):e1365–1377. DOI:10.1212/WNL.0000000000009169
   PubMed Web of Science ®Google Scholar
• Ailani J, McAllister P, Winner PK, et al. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial. BMC neurol. [Published 2022 Jun 3] 2022;22(1):205.
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15(4):382–390.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037. DOI:10.1177/0333102418759786
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Reuter U, Goadsby PJ, et al. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study. J Neurol Neurosurg Psychiatry. 2022;93(3):254–262.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020;95(5):e469–479. DOI:10.1212/WNL.0000000000010019
   PubMed Web of Science ®Google Scholar
• Wang SJ, AA R Jr, Saravia B, et al. Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia. 2021;41(13):1285–1297.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1081–1090.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–1100.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008. DOI:10.1001/jama.2018.4853
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial [published correction appears in Lancet. 2019 Oct 29]. Lancet. 2019;394(10203):1030–1040.
   PubMed Web of Science ®Google Scholar
• Ashina M, Cohen JM, Galic M, et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. [Published 2021 Jul 10] 2021;22(1):68.
   PubMed Web of Science ®Google Scholar
• Oakes TMM, Skljarevski V, Zhang Q, et al. Safety of galcanezumab in patients with episodic migraine: a randomized placebo-controlled dose-ranging Phase 2b study. Cephalalgia. 2018;38(6):1015–1025.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–2221.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 Randomized Clinical Trial [published correction appears in JAMA Neurol. 2019 Jul 1;76(7): 872]. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–825.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial [published correction appears in Lancet Neurol. 2020 Nov;19(11): e10]. Lancet Neurol. 2020;19(9):727–737.
   PubMed Web of Science ®Google Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695–706.
   PubMed Web of Science ®Google Scholar
• Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache. 2023;63(1):79–88.
   PubMed Web of Science ®Google Scholar
• Johnston K, Harris L, Powell L, et al. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain. [Published 2022 Jan 17] 2022;23(1):10.
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.
   PubMed Web of Science ®Google Scholar
• Johnston KM, L’Italien G, Popoff E, et al. Mapping migraine-specific quality of life to health state utilities in patients receiving rimegepant. Adv Ther. 2021;38(10):5209–5220.
   PubMed Web of Science ®Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. [Published 2017 Sep 25] 2017;18(1):96.
   PubMed Web of Science ®Google Scholar
• de Vries Lentsch S, van der Arend BWH, VanDenbrink A M, et al. Blood pressure in patients with migraine treated with monoclonal Anti-CGRP (Receptor) Antibodies: a Prospective Follow-up Study. Neurology. 2022;99(17):e1897–1904.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Tepper SJ, Ailani J, et al. Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache. 2021;61(9):1411–1420.
   PubMed Web of Science ®Google Scholar
• MaassenVandenbrink A, Meijer J, Villalón CM, et al. Wiping Out CGRP: potential Cardiovascular Risks. Trends Pharmacol Sci. 2016;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Cetta I, Messina R, Colombo B, et al. Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report. J Neurol. 2022;269(9):5170–5172.
   PubMed Web of Science ®Google Scholar
• Perino J, Corand V, Laurent E, et al. Myocardial infarction associated with erenumab: a case report. Pharmacotherapy. 2022;42(7):585–589.
   PubMed Web of Science ®Google Scholar
• Holzer P, Holzer-Petsche U. Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide’s motor-stimulating and prosecretory function in the intestine. Front Physiol. [Published 2022 Jan 11] 2022;12:820006.
   PubMed Web of Science ®Google Scholar
• Kudrow D, Nguyen L, Semler J, et al. A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist. Headache. 2022;62(9):1164–1176.
   PubMed Web of Science ®Google Scholar
• Assas MB. Anti-migraine agents from an immunological point of view [published correction appears in. J Transl MedJ Transl Med. 2021 2021 Aug 9Published 2021 Jan 6;1919(11):23.
   PubMed Web of Science ®Google Scholar
• Ray JC, Allen P, Bacsi A, et al. Inflammatory complications of CGRP monoclonal antibodies: a case series. J Headache Pain. [Published 2021 Oct 9] 2021;22(1):121.
   PubMed Web of Science ®Google Scholar
• Ruiz M, Cocores A, Tosti A, et al. Alopecia as an emerging adverse event to CGRP monoclonal antibodies: cases Series, evaluation of FAERS, and literature review. Cephalalgia. 2023;43(2):3331024221143538.
   Web of Science ®Google Scholar
• Gérard AO, Merino D, Van Obberghen EK, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database. J Headache Pain. [Published 2022 May 3] 2022;23(1):53.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Sapra S, Shah N, et al. Direct and indirect healthcare resource utilization and costs among migraine patients in the United States. Headache. 2018;58(5):700–714.
   PubMed Web of Science ®Google Scholar
• Guo S, Jansen-Olesen I, Olesen J, et al. Role of PACAP in migraine: an alternative to CGRP? Neurobiol Dis. 2023;176:105946.
   PubMed Web of Science ®Google Scholar
• Bhakta M, Vuong T, Taura T, et al. Migraine therapeutics differentially modulate the CGRP pathway. Cephalalgia. 2021;41(5):499–514.
   PubMed Web of Science ®Google Scholar
• Shibata Y. Migraine pathophysiology revisited: proposal of a new molecular theory of migraine pathophysiology and headache diagnostic criteria. Int J Mol Sci. 2022 Published 2022 Oct 27;23(21):13002.
   PubMed Web of Science ®Google Scholar
• Ashina M. Targeting enkephalins and pituitary adenylate cyclase-activating polypeptide (PACAP) in migraine. Brain. 2022;145(8):2619–2620.
   PubMed Web of Science ®Google Scholar
• Pellesi L, Al-Karagholi MA, De Icco R, et al. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial. JAMA Netw Open. [Published 2021 Aug 2] 2021;4(8):e2118543.
   PubMed Web of Science ®Google Scholar
• Al-Karagholi MA, Hansen JM, Guo S, et al. Opening of ATP-sensitive potassium channels causes migraine attacks: a new target for the treatment of migraine. Brain. 2019;142(9):2644–2654.
   PubMedGoogle Scholar
• Al-Karagholi MA, Ghanizada H, Waldorff Nielsen CA, et al. Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraine. Pain. 2021;162(10):2512–2520.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Terhart M, Overeem LH, et al. Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. 2022;42(4–5):326–334. DOI:10.1177/03331024211046617
   PubMed Web of Science ®Google Scholar
• Terhart M, Mecklenburg J, Neeb L, et al. Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies. J Headache Pain. 2021;22(1):158.
   PubMed Web of Science ®Google Scholar